Actionable news
All posts from Actionable news
Actionable news in MCRB: Seres Therapeutics Inc,

Seres Therapeutics: A Matter Of Details

A "surprise" fail on the P2 SER-109 trial caused the stock to plummet 70%.

Insider selling began in March - right when enrollment completed for P2.

There is one key difference between P1 and P2.

Seres Therapeutics (NASDAQ:MCRB) Postulation

I awoke today to something I absolutely did not expect - the report of Seres Therapeutics down over 70% on bad "surprise" data. It didn't make sense.

How can you have Phase I data that showed 96.7% (29 of 30) of the patients achieving clinical resolution by week 8 and Phase II data that showed no difference between placebo:

Based on 8-week data, CDI recurrence occurred in 44% of subjects...